09:26 AM EDT, 07/30/2024 (MT Newswires) -- ZYUS Life Sciences ( ZLSCF ) , which is developing cannabinoid-based pharmaceutical drug candidates for pain management, on Tuesday said it has received a No Objection Letter (NOL) from Health Canada for a proof-of-concept (POC) trial for its lead drug candidate, Trichomylin softgel capsules.
The POC trial aims to assess the preliminary efficacy and feasibility of Trichomylin in patients with advanced cancer and moderate to severe cancer-related pain.